Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 6,417Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Asmanex

02 3Dulera

03 10Nasonex

PharmaCompass

01

Brand Name : Nasonex

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Nasonex

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 218

2019 Revenue in Millions : 293

Growth (%) : -26

blank

02

Brand Name : Dulera

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Dulera

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 190

2020 Revenue in Millions : 222

Growth (%) : -14

blank

03

Brand Name : Nasonex

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Nasonex

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 206

2020 Revenue in Millions : 218

Growth (%) : -6

blank

04

Brand Name : Asmanex

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Asmanex

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 63

2020 Revenue in Millions : 83

Growth (%) : -24

blank

05

Brand Name : Nasonex

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Nasonex

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 238

2021 Revenue in Millions : 206

Growth (%) : 16

blank

06

Brand Name : Dulera

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Dulera

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 180

2021 Revenue in Millions : 190

Growth (%) : -5

blank

07

Brand Name : Dulera

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Dulera

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2023 Revenue in Millions : 194

2022 Revenue in Millions : 180

Growth (%) : 8

blank

08

Brand Name : Nasonex

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Nasonex

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2023 Revenue in Millions : 253

2022 Revenue in Millions : 238

Growth (%) : 6

blank

09

Brand Name : Nasonex

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Nasonex

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2015 Revenue in Millions : 1,099

2014 Revenue in Millions : 858

Growth (%) : -22%

blank

10

Brand Name : Nasonex

Mometasone Furoate

arrow
CPhI India 2024
Not Confirmed

Brand Name : Nasonex

arrow
CPhI India 2024
Not Confirmed

Mometasone Furoate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2014 Revenue in Millions : -17.70%

2013 Revenue in Millions :

Growth (%) :

blank